Subscribe to RSS
DOI: 10.1055/a-1936-3123
Immunvermittelte Sinus- und Hirnvenenthrombosen: VITT und prä-VITT als Modellerkrankung
Cerebral Venous and Sinus Thrombosis with Immunological Pathogenesis: VITT and Pre-VITTZusammenfassung
In diesem Übersichtsartikel beschreiben wir die klinischen und paraklinischen Charakteristika der Vakzin-induzierten immunthrombotischen Thrombozytopenie (VITT) und fassen den gegenwärtigen Kenntnisstand zur Pathogenese zusammen. Bei der VITT bilden sich 5–20 Tage nach einer Impfung mit einem Adenovirus-vektorbasiertem SARS-CoV-2-Vakzin (AstraZeneca oder Johnson & Johnson) lebensbedrohliche Thrombosen aus, vor allem in den zerebralen Sinus und Hirnvenen. Laborchemisch zeigt sich eine typische Thrombozytopenie mit erhöhten D-Dimeren. Der Pathogenese liegen immunologische Prozesse zugrunde, die Ähnlichkeiten mit der Heparin-induzierten Thrombozytopenie aufweisen: so geht die VITT mit hochtitrigem Immunoglobulin G gegen das thrombozytäre Protein Plättchenfaktor 4 (PF4) einher. Durch die Interaktion mit dem Impfstoff wird PF4 so verändert, dass es von Antikörper-produzierenden Zellen des Immunsystems erkannt wird. Die so produzierten Anti-PF4-Antikörper führen über thrombozytäre FcγIIa-Rezeptoren zu einer Plättchenaktivierung. Der Nachweis plättchenaktivierender Anti-PF4-Antikörper bestätigt die Diagnose einer VITT. Antikoagulanzien, die die Bildung von Thrombin oder Thrombin selbst blockieren und hochdosiertes i. v.-Immunglobulin G, das die Fcγ-Rezeptor-vermittelte Zellaktivierung inhibiert, stellen die wirksame und kausale Behandlung der VITT dar. Bei Patienten mit katastrophalem Verlauf kann ein Plasmaaustausch versucht werden. Bei einigen Patienten ist ein prä-VITT Syndrom als Prodromalstadium zu beoachten, das sich typischerweise mit Kopfschmerzen manifestieren kann und dessen frühe Behandlung hilft, thrombotische Komplikationen zu vermeiden. Die spezifische Dynamik der VITT-assozierten Immunreaktion entspricht einer transienten, sekundären Immunantwort. Aktuelle Studien gehen der Frage nach, wie PF4 an unterschiedliche adenovirale Proteine bindet und beleuchten die Rolle von anderen Impfstoff-Bestandteilen als potentielle Liganden für die PF4-Bindung. Einige dieser Faktoren sind auch an der Etablierung eines proinflammatorischen Milieus („danger signal“) beteiligt, das unmittelbar nach der Impfung die 1. Phase der VITT-Pathogenese triggert. Sobald in der 2. Phase der VITT-Pathogenese hohe Titer von Anti-PF4-Antikörper gebildet sind, aktivieren diese neben Thrombozyten auch Granulozyten. In einem als NETose (von „neutrophil extracellular traps“) bezeichneten Prozess setzen aktivierte Granulozyten dabei DNA frei, mit der PF4 weitere Komplexe bildet, an die Anti-PF4-Antikörper binden. Dies verstärkt die Fcγ-Rezeptor-vermittelte Zellaktivierung weiter mit der Folge einer ausgeprägten Thrombin-Bildung. Zum Ende des Artikels geben wir einen Ausblick, welchen Einfluss die bisherigen Erkenntnisse zur VITT auf weitere globale Impfkampagnen gegen SARS-CoV-2 haben und beleuchten, wie Anti-PF4-Antikörper jenseits von VITT und HIT auch eine Rolle bei seltenen Erkrankungen spielen, die mit rezidivierenden venösen und arteriellen Thrombosen einhergehen.
Abstract
In this review, we summarise the current knowledge on vaccine-induced immune thrombotic thrombocytopenia (VITT) and new insights into its underlying pathogenesis. VITT is characterised by severe thromboses occurring 5–20 days after vaccination with an adenoviral vector-based SARS-CoV-2 vaccine (AstraZeneca or Johnson & Johnson). Thromboses typically involve the cerebral sinus and venous system. Routine laboratory analyses show thrombocytopenia and high D-dimer levels. The pathogenesis is based on immunological processes similar to those in heparin-induced thrombocytopenia. Accordingly, VITT is associated with high-titre immunoglobulin G directed against platelet factor 4 (PF4). Interaction with adenoviral vector-based vaccines leads to modifications of PF4 allowing antibody-producing cells to identify PF4. Anti-PF4 antibodies activate platelets through FcγIIa receptors. The detection of platelet-activating anti-PF4 antibodies confirms the diagnosis of VITT. Treatment is based on anticoagulation, which inhibits thrombin itself or thrombin formation, and high-dose intravenous immunoglobulin G, which inhibits cell activation via FcγIIa receptors. In severe cases, plasma exchange could also be an option. In some patients, a pre-VITT syndrome precedes VITT. Pre-VITT patients typically present with severe headache before thromboses are manifest. The early identification of a pre-VITT syndrome allows for the prevention of thrombotic complications. The specific dynamics of the immune reaction in VITT correspond to a transient, secondary immune response. Current studies address how PF4 binds to different adenoviral proteins and investigate the functional role of other vaccine components. Some of these factors contribute to the induction of a pro-inflammatory “danger signal” that triggers the first stage of VITT pathogenesis. In the second stage, high-titre anti-PF4 antibodies activate platelets and granulocytes. In a process called NETosis (“neutrophil extracellular traps”), activated granulocytes release DNA. Anti-PF4 antibodies then bind to complexes of PF4 and DNA. This enhances further cell activation via Fcγ receptors and consequently also the formation of thrombin. At the end of the article, we comment on how the current knowledge on VITT may influence global vaccination campaigns against SARS-CoV-2 and we address how anti-PF4 antibodies may be involved in recurrent arterial and venous thromboses not associated with VITT and HIT.
Publication History
Article published online:
02 November 2022
© 2022. Thieme. All rights reserved.
Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart,
Germany
-
Literatur
- 1 Long B, Bridwell R, Gottlieb M. Thrombosis with thrombocytopenia syndrome associated with COVID-19 vaccines. Am J Emerg Med 2021; 49: 58-61 DOI: 10.1016/j.ajem.2021.05.054.. PMID: 34062319
- 2 See I, Su JR, Lale A. et al. US Case Reports of Cerebral Venous Sinus Thrombosis with Thrombocytopenia after Ad26.COV2.S Vaccination, March 2 to April 21, 2021. JAMA 2021; 325: 2448-2456
- 3 European Medicines Agency (EMA) Vaxzevria (previously covid-19 vaccine astra zeneca): Epar – product information. 2021 [Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/vaxzevria-previously-covid-19-vaccine-astrazeneca
- 4 European Medicines Agency & Healthcare products Regulatory Agency- Public assessment report authorisation for temporary supply – covid-19 vaccine astrazeneca, solution for injection in multidose container covid-19 vaccine (chadox1-s [recombinant]). 2021 [Available from: https://www.ema.europa.eu/en/documents/assessment-report/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-public-assessment-report_en.pdf
- 5 European Medicines Agency (EMA) COVID-19 Vaccine Janssen (COVID-19 vaccine (Ad26.COV2-S [recombinant])) 2021 [Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/covid-19-vaccine-janssen
- 6 Pavord S, Scully M, Hunt BJ. et al. Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis. N Engl J Med 2021; 385: 1680-1689 DOI: 10.1056/NEJMoa2109908.. PMID: 34379914
- 7 Baldini T, Asioli GM, Romoli M. et al. Cerebral venous thrombosis and severe acute respiratory syndrome coronavirus-2 infection: A systematic review and meta-analysis. Eur J Neurol 2021; 28: 3478-3490 DOI: 10.1111/ene.14727.. PMID: 33426733
- 8 Krzywicka K, van de Munckhof A, Zimmermann J. et al. Cerebral venous thrombosis due to vaccine-induced immune thrombotic thrombocytopenia after a second ChAdOx1 nCoV-19 dose. Blood 2022; 139: 2720-2724 DOI: 10.1182/blood.2021015329.. PMID: 35263427
- 9 Schultz NH, Sørvoll IH, Michelsen AE. et al. Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. N Engl J Med 2021; 384: 2124-2130 DOI: 10.1056/NEJMoa2104882.. PMID: 33835768
- 10 Greinacher A, Thiele T, Warkentin TE. et al. Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. N Engl J Med 2021; 384: 2092-2101 DOI: 10.1056/NEJMoa2104840.. PMID: 33835769
- 11 Scully M, Singh D, Lown R. et al. Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination. N Engl J Med 2021; 384: 2202-2211 DOI: 10.1056/NEJMoa2105385.. PMID: 33861525
- 12 Sánchez van Kammen M, Aguiar de Sousa D, Poli S. et al. Cerebral Venous Sinus Thrombosis With Thrombocytopenia Syndrome Study Group. Characteristics and Outcomes of Patients With Cerebral Venous Sinus Thrombosis in SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia. JAMA Neurol 2021; 78: 1314-1323 DOI: 10.1001/jamaneurol.2021.3619.. PMID: 34581763
- 13 Nicolai L, Leunig A, Pekayvaz K. et al. Thrombocytopenia and splenic platelet directed immune responses after intravenous ChAdOx1 nCov-19 administration. Blood 2022; blood.2021014712 DOI: 10.1182/blood.2021014712. Epub ahead of print. PMID: 35486845; PMCID: PMC9060731.
- 14 Salih F, Schönborn L, Kohler S. et al. Vaccine-Induced Thrombocytopenia with Severe Headache. N Engl J Med 2021; 385: 2103-2105 DOI: 10.1056/NEJMc2112974.. PMID: 34525282
- 15 Salih F, Kohler S, Schönborn L. et al. Early recognition and treatment of pre-VITT syndrome after adenoviral vector-based SARS-CoV-2 vaccination may prevent from thrombotic complications: review of published cases and clinical pathway. Eur Heart J Open 2022; 2: 1-10 DOI: 10.1093/ehjopen/oeac036.
- 16 van de Munckhof A, Krzywicka K, de Sousa DA. et al. Declining mortality of cerebral venous sinus thrombosis with thrombocytopenia after SARS-CoV-2 vaccination. Eur J Neurol 2022; 29: 339-344
- 17 American Society of Hemoatology. Vaccine-induced Immune Thrombotic Thrombocytopenia (Version 1.9; last updated May 9,2022). Link: https://www.hematology.org/covid-19/vaccine-induced-immune- thrombotic-thrombocytopenia
- 18 Schönborn L, Greinacher A. Longitudinal Aspects of VITT. Semin Hematol 2022; 59: 108-114 DOI: 10.1053/j.seminhematol.2022.03.001.. PMID: 35512899
- 19 Schönborn L, Thiele T, Kaderali L. et al. Most anti-PF4 antibodies in vaccine-induced immune thrombotic thrombocytopenia are transient. Blood 2022; 139: 1903-1907 DOI: 10.1182/blood.2021014214.. PMID: 35113987
- 20 Krauel K, Pötschke C, Weber C. et al. Platelet factor 4 binds to bacteria, [corrected] inducing antibodies cross-reacting with the major antigen in heparin-induced thrombocytopenia. Blood 2011; 117: 1370-1378 DOI: 10.1182/blood-2010-08-301424..
- 21 Palankar R, Kohler TP, Krauel K. et al. Platelets kill bacteria by bridging innate and adaptive immunity via platelet factor 4 and FcgammaRIIA. J Thromb Haemost 2018; 16: 1187-1197
- 22 Zheng Y, Wang AW, Yu M. et al. B-cell tolerance regulates production of antibodies causing heparin-induced thrombocytopenia. Blood 2014; 123: 931-934
- 23 Krauel K, Schulze A, Jouni R. et al. Further insights into the anti-PF4/heparin IgM immune response. Thromb Haemost 2016; 115: 752-761
- 24 Delcea M, Greinacher A. Biophysical tools to assess the interaction of PF4 with polyanions. Thromb Haemost 2016; 116: 783-791
- 25 Nguyen TH, Greinacher A, Delcea M. Quantitative description of thermodynamic and kinetic properties of the platelet factor 4/heparin bonds. Nanoscale 2015; 7: 10130-10139
- 26 Kreimann M, Brandt S, Krauel K. et al. Binding of anti-platelet factor 4/heparin antibodies depends on the thermodynamics of conformational changes in platelet factor 4. Blood 2014; 124: 2442-2449
- 27 Hursting MJ, Pai PJ, McCracken JE. et al. Platelet factor 4/heparin antibodies in blood bank donors. Am J Clin Pathol 2010; 134: 774-780 DOI: 10.1309/AJCPG0MNR5NGKNFX.. PMID: 20959660
- 28 Greinacher A, Holtfreter B, Krauel K. et al. Association of natural anti-platelet factor 4/heparin antibodies with periodontal disease. Blood 2011; 118: 1395-1401 DOI: 10.1182/blood-2011-03-342857.. PMID: 21659541
- 29 Othman M, Baker AT, Gupalo E. et al. To clot or not to clot? Ad is the question-Insights on mechanisms related to vaccine-induced thrombotic thrombocytopenia. J Thromb Haemost 2021; 19: 2845-2856 DOI: 10.1111/jth.15485.. PMID: 34351057
- 30 Othman M, Labelle A, Mazzetti I. et al. Adenovirus-induced thrombocytopenia: the role of von Willebrand factor and P-selectin in mediating accelerated platelet clearance. Blood 2007; 109: 2832-2839
- 31 Baker AT, Boyd RJ, Sarkar D. et al. ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome. Sci Adv 2021; 7 eabl8213
- 32 Michalik S, Siegerist F, Palankar R. et al. Comparative analysis of ChAdOx1 nCoV-19 and Ad26.COV2.S SARS-CoV-2 vector vaccines. Haematologica 2022; 107: 947-957 DOI: 10.3324/haematol.2021.280154.. PMID: 35045692
- 33 Holen HL, Zernichow L, Fjelland KE. et al. Ephrin-B3 binds to a sulfated cell-surface receptor. Biochem J 2011; 433: 215-223 DOI: 10.1042/BJ20100865.. PMID: 20925654
- 34 Alban S, Neupane S, Girreser U. et al. The COVID-19 vaccine ChAdOx1-S is not contaminated with sulfated glycosaminoglycans. J Thromb Haemost 2022; 20: 777-780 DOI: 10.1111/jth.15633.. PMID: 34971474
- 35 Jaax ME, Krauel K, Marschall T. et al. Complex formation with nucleic acids and aptamers alters the antigenic properties of platelet factor 4. Blood 2013; 122: 272-281 DOI: 10.1182/blood-2013-01-478966.. PMID: 23673861
- 36 Choi PY. Thrombotic Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. N Engl J Med 2021; 385: e11 DOI: 10.1056/NEJMc2107227.. PMID: 34133852
- 37 Ramge P, Unger RE, Oltrogge JB. et al. Polysorbate-80 coating enhances uptake of polybutylcyanoacrylate (PBCA)-nanoparticles by human and bovine primary brain capillary endothelial cells. Eur J Neurosci 2000; 12: 1931-1940 DOI: 10.1046/j.1460-9568.2000.00078.x.. PMID: 10886334
- 38 Greinacher A, Selleng K, Palankar R. et al. Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia. Blood 2021; 138: 2256-2268 DOI: 10.1182/blood.2021013231.. PMID: 34587242
- 39 Huynh A, Kelton JG, Arnold DM. et al. Antibody epitopes in vaccine-induced immune thrombotic thrombocytopaenia. Nature 2021; 596: 565-569 DOI: 10.1038/s41586-021-03744-4.. PMID: 34233346
- 40 Singh A, Toma F, Uzun G. et al. The interaction between anti-PF4 antibodies and anticoagulants in vaccine-induced thrombotic thrombocytopenia. Blood 2022; 139: 3430-3438 DOI: 10.1182/blood.2021013839.. PMID: 35679071
- 41 Vayne C, Palankar R, Billy S. et al. The deglycosylated form of 1E12 inhibits platelet activation and prothrombotic effects induced by VITT antibodies. Haematologica 2022; DOI: 10.3324/haematol.2021.280251.. PMID: 35385923
- 42 See I, Lale A, Marquez P. et al. Case Series of Thrombosis With Thrombocytopenia Syndrome After COVID-19 Vaccination-United States, December 2020 to August 2021. Ann Intern Med 2022; 175: 513-522 DOI: 10.7326/M21-4502.. PMID: 35038274
- 43 Paul-Ehrlich-Institut G. Sicherheitsbericht: Verdachtsfälle von Nebenwirkungen und Impfkomplikationen nach Impfung zum Schutz vor COVID-19 seit Beginn der Impfkampagne am 27.12.2020 bis zum 30.09.2021. Link: https://www.pei.de/SharedDocs/Downloads/DE/newsroom/dossiers/sicherheitsberichte/sicherheitsbericht-27-12-20-bis-30-09-21.pdf?__blob=publicationFile&v=9
- 44 Li R, Liu J, Wu S. et al. Toll-like receptor 4 signalling regulates antibody response to adenoviral vector-based vaccines by imprinting germinal centre quality. Immunology 2018; 155: 251-262 DOI: 10.1111/imm.12957.. PMID: 29876918
- 45 Pfueller SL, Logan D, Tran TT. et al. Naturally occurring human IgG antibodies to intracellular and cytoskeletal components of human platelets. Clin Exp Immunol 1990; 79: 367-373 DOI: 10.1111/j.1365-2249.1990.tb08097.x.. PMID: 2107990
- 46 Gao X, Kouklis P, Xu N. et al. Reversibility of increased microvessel permeability in response to VE-cadherin disassembly. Am J Physiol Lung Cell Mol Physiol 2000; 279: L1218-L1225 DOI: 10.1152/ajplung.2000.279.6.L1218.. PMID: 11076812
- 47 Uzun G, Althaus K, Bakchoul T. No Correlation between Anti-PF4 and Anti–SARS-CoV-2 Antibodies after ChAdOx1 nCoV-19 Vaccination. N Eng. J Med 2021; 385: 1334-1336
- 48 Greinacher A, Schönborn L, Siegerist F. et al. Pathogenesis of vaccine-induced immune thrombotic thrombocytopenia (VITT). Semin Hematol 2022; 59: 97-107 DOI: 10.1053/j.seminhematol.2022.02.004.. Epub 2022 Feb 23. PMID: 35512907
- 49 Schönborn L, Thiele T, Kaderali L. et al. Decline in Pathogenic Antibodies over Time in VITT. N Eng J Med 2021; 385: 1815-1816
- 50 Lindhoff-Last E, Schönborn L, Piorkowski M. et al. Heterogeneity of Vaccine-Induced Immune Thrombotic Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination and Safety of Second Vaccination with BNT162b2. Thromb Haemost 2022; 122: 304-307
- 51 Lacy J, Pavord S, Brown KEVITT. and Second Doses of Covid-19 Vaccine. N Eng. J Med 2022; 386: 95
- 52 Warkentin TE, Sheppard JA. Serological investigation of patients with a previous history of heparin-induced thrombocytopenia who are reexposed to heparin. Blood 2014; 123: 2485-2493
- 53 Lubenow N, Hinz P, Thomaschewski S. et al. The severity of trauma determines the immune response to PF4/heparin and the frequency of heparin-induced thrombocytopenia. Blood 2010; 115: 1797-1803 DOI: 10.1182/blood-2009-07-231506.. PMID: 19965682
- 54 Greinacher A. Heparin-Induced Thrombocytopenia. N Eng J Med 2015; 373: 1883-1884
- 55 Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Eng J Med 2001; 344: 1286-1292
- 56 Günther A, Brämer D, Pletz MW. Complicated Long Term Vaccine Induced Thrombotic Immune Thrombocytopenia – A Case Report. Vaccines (Basel) 2021; 9: 1344 DOI: 10.3390/vaccines9111344.. PMID: 34835275
- 57 Khandelwal S, Ravi J, Rauova L. et al. Polyreactive IgM initiates complement activation by PF4/heparin complexes through the classical pathway. Blood 2018; 132: 2431-2440 DOI: 10.1182/blood-2018-03-834598.. PMID: 30309891
- 58 Arepally GM, Cines DB. Pathogenesis of heparin-induced thrombocytopenia. Transl Res 2020; 225: 131-140
- 59 Thiele T, Ulm L, Holtfreter S. et al. Frequency of positive anti-PF4/polyanion antibody tests after COVID-19 vaccination with ChAdOx1 nCoV-19 and BNT162b2. Blood 2021; 138: 299-303 DOI: 10.1182/blood.2021012217.. PMID: 33988688
- 60 Thiele T, Weisser K, Schönborn L. et al. Laboratory confirmed vaccine-induced immune thrombotic thrombocytopenia: Retrospective analysis of reported cases after vaccination with ChAdOx-1 nCoV-19 in Germany. Lancet Reg Health Eur 2022; 12: 100270 DOI: 10.1016/j.lanepe.2021.100270.. PMID: 34901912
- 61 Uzun G, Althaus K, Singh A. et al. The use of IV immunoglobulin in the treatment of vaccine-induced immune thrombotic thrombocytopenia. Blood 2021; 138: 992-996 DOI: 10.1182/blood.2021012479.. PMID: 34166507
- 62 Bourguignon A, Arnold DM, Warkentin TE. et al. Adjunct Immune Globulin for Vaccine-Induced Immune Thrombotic Thrombocytopenia. N Engl J Med 2021; 385: 720-728 DOI: 10.1056/NEJMoa2107051.. PMID: 34107198
- 63 Althaus K, Möller P, Uzun G. et al. Antibody-mediated procoagulant platelets in SARS-CoV-2-vaccination associated immune thrombotic thrombocytopenia. Haematologica 2021; 106: 2170-2179 DOI: 10.3324/haematol.2021.279000.. PMID: 34011137
- 64 Holm S, Kared H, Michelsen AE. et al. Immune complexes, innate immunity, and NETosis in ChAdOx1 vaccine-induced thrombocytopenia. Eur Heart J 2021; 42: 4064-4072 DOI: 10.1093/eurheartj/ehab506.. PMID: 34405870
- 65 Beng C, Halina L, Jose P. et al. NETosis and thrombosis in vaccine-induced immune thrombotic thrombocytopenia. Nature Portfolio. 2022 preprint
- 66 Arepally GM, Padmanabhan A. Heparin-Induced Thrombocytopenia: A Focus on Thrombosis. Arterioscler Thromb Vasc Biol 2021; 41: 141-152 DOI: 10.1161/Atvbaha.120.315445.. PMID: 33267665
- 67 Blank M, Shoenfeld Y, Tavor S. et al. Anti-platelet factor 4/heparin antibodies from patients with heparin-induced thrombocytopenia provoke direct activation of microvascular endothelial cells. Int Immunol 2002; 14: 121-129 DOI: 10.1093/intimm/14.2.121.. PMID: 11809731
- 68 Johansen S, Laegreid IJ, Ernstsen SL. et al. Thrombosis and thrombocytopenia after HPV vaccination. J Thromb Haemost 2022; 20: 700-704 DOI: 10.1111/jth.15604.. PMID: 34817130
- 69 Greinacher A, Langer F, Schönborn L. et al. Platelet-activating anti-PF4 antibodies mimic VITT antibodies in an unvaccinated patient with monoclonal gammopathy. Haematologica 107: 1219-1221 DOI: 10.3324/haematol.2021.280366.. PMID: 34965704
- 70 Faille DH-NMO A, Amiral J, Huisse MG. et al. Isolation of a monoclonal IgG kappa with functional autoantibody activity against platelet factor 4/heparin from a patient with a monoclonal gammopathy of undetermined significance and clinically overt heparin thrombocytopenia. Res Pract Thromb Haemost 2017; 1: 1355